BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 38596285)

  • 1. TROP2 is highly expressed in triple-negative breast cancer CTCs and is a potential marker for epithelial mesenchymal CTCs.
    Liao Q; Zhang R; Ou Z; Ye Y; Zeng Q; Wang Y; Wang A; Chen T; Chai C; Guo B
    Mol Ther Oncol; 2024 Mar; 32(1):200762. PubMed ID: 38596285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
    Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
    Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigating circulating tumor cells and distant metastases in patient-derived orthotopic xenograft models of triple-negative breast cancer.
    Ramani VC; Lemaire CA; Triboulet M; Casey KM; Heirich K; Renier C; Vilches-Moure JG; Gupta R; Razmara AM; Zhang H; Sledge GW; Sollier E; Jeffrey SS
    Breast Cancer Res; 2019 Aug; 21(1):98. PubMed ID: 31462307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition.
    Gorges TM; Tinhofer I; Drosch M; Röse L; Zollner TM; Krahn T; von Ahsen O
    BMC Cancer; 2012 May; 12():178. PubMed ID: 22591372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Classification of circulating tumor cells by epithelial-mesenchymal transition markers.
    Wu S; Liu S; Liu Z; Huang J; Pu X; Li J; Yang D; Deng H; Yang N; Xu J
    PLoS One; 2015; 10(4):e0123976. PubMed ID: 25909322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of circulating tumor cells and evaluation of epithelial-mesenchymal transition patterns of circulating tumor cells in ovarian cancer.
    Jie XX; Zhang M; Du M; Cai QQ; Cong Q; Xu CJ; Zhang XY
    Transl Cancer Res; 2022 Aug; 11(8):2636-2646. PubMed ID: 36093536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EpCAM-Independent Enrichment of Circulating Tumor Cells in Metastatic Breast Cancer.
    Schneck H; Gierke B; Uppenkamp F; Behrens B; Niederacher D; Stoecklein NH; Templin MF; Pawlak M; Fehm T; Neubauer H;
    PLoS One; 2015; 10(12):e0144535. PubMed ID: 26695635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular detection of epithelial-mesenchymal transition markers in circulating tumor cells from pancreatic cancer patients: Potential role in clinical practice.
    Zhao XH; Wang ZR; Chen CL; Di L; Bi ZF; Li ZH; Liu YM
    World J Gastroenterol; 2019 Jan; 25(1):138-150. PubMed ID: 30643364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epithelial-to-mesenchymal transition leads to disease-stage differences in circulating tumor cell detection and metastasis in pre-clinical models of prostate cancer.
    Lowes LE; Goodale D; Xia Y; Postenka C; Piaseczny MM; Paczkowski F; Allan AL
    Oncotarget; 2016 Nov; 7(46):76125-76139. PubMed ID: 27764810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epithelial-Mesenchymal-Transition-Like Circulating Tumor Cell-Associated White Blood Cell Clusters as a Prognostic Biomarker in HR-Positive/HER2-Negative Metastatic Breast Cancer.
    Guan X; Li C; Li Y; Wang J; Yi Z; Liu B; Chen H; Xu J; Qian H; Xu B; Ma F
    Front Oncol; 2021; 11():602222. PubMed ID: 34150608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells.
    Guan X; Ma F; Liu S; Wu S; Xiao R; Yuan L; Sun X; Yi Z; Yang H; Xu B
    Oncotarget; 2016 Oct; 7(40):65993-66002. PubMed ID: 27602758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spatial heterogeneity in epithelial to mesenchymal transition properties of circulating tumor cells associated with distant recurrence in pancreatic cancer patients.
    Dong X; Ma Y; Zhao X; Tian X; Sun Y; Yang Y; Zhao X
    Ann Transl Med; 2020 Jun; 8(11):676. PubMed ID: 32617296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role and molecular mechanism of Trop2 induced epithelial-mesenchymal transition through mediated β-catenin in gastric cancer.
    Zhao W; Jia L; Kuai X; Tang Q; Huang X; Yang T; Qiu Z; Zhu J; Huang J; Huang W; Feng Z
    Cancer Med; 2019 Mar; 8(3):1135-1147. PubMed ID: 30632714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
    Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
    Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Looking for a Better Characterization of Triple-Negative Breast Cancer by Means of Circulating Tumor Cells.
    Abreu M; Cabezas-Sainz P; Pereira-Veiga T; Falo C; Abalo A; Morilla I; Curiel T; Cueva J; Rodríguez C; Varela-Pose V; Lago-Lestón R; Mondelo P; Palacios P; Moreno-Bueno G; Cano A; García-Caballero T; Pujana MÁ; Sánchez-Piñón L; Costa C; López R; Muinelo-Romay L
    J Clin Med; 2020 Jan; 9(2):. PubMed ID: 32012729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream® in patients with breast cancer treated with primary systemic therapy.
    Le Du F; Fujii T; Kida K; Davis DW; Park M; Liu DD; Wu W; Chavez-MacGregor M; Barcenas CH; Valero V; Tripathy D; Reuben JM; Ueno NT
    PLoS One; 2020; 15(3):e0229903. PubMed ID: 32214335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.
    Yoshida T; Ozawa Y; Kimura T; Sato Y; Kuznetsov G; Xu S; Uesugi M; Agoulnik S; Taylor N; Funahashi Y; Matsui J
    Br J Cancer; 2014 Mar; 110(6):1497-505. PubMed ID: 24569463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor shedding and metastatic progression after tumor excision in patient-derived orthotopic xenograft models of triple-negative breast cancer.
    Razmara AM; Sollier E; Kisirkoi GN; Baker SW; Bellon MB; McMillan A; Lemaire CA; Ramani VC; Jeffrey SS; Casey KM
    Clin Exp Metastasis; 2020 Jun; 37(3):413-424. PubMed ID: 32335861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanoroughened adhesion-based capture of circulating tumor cells with heterogeneous expression and metastatic characteristics.
    Chen W; Allen SG; Reka AK; Qian W; Han S; Zhao J; Bao L; Keshamouni VG; Merajver SD; Fu J
    BMC Cancer; 2016 Aug; 16():614. PubMed ID: 27501846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating Tumor Cells and Implications of the Epithelial-to-Mesenchymal Transition.
    Lowes LE; Allan AL
    Adv Clin Chem; 2018; 83():121-181. PubMed ID: 29304900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.